Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/13/2025

Beta Blockers Post-AMI with Preserved LVEF: Current Evidence Summary

Key Evidence and Guideline Recommendations

  • The European Society of Cardiology recommends beta-blockers as initial treatment for symptom control in chronic coronary syndrome, but notes the clinical benefit beyond improving symptoms is largely unknown in patients with CAD without prior MI and normal LVEF 1, 2
  • The American College of Cardiology/American Heart Association recommends early initiation of oral beta-blocker therapy in patients with ACS without contraindications to reduce reinfarction and ventricular arrhythmias 6
  • Beta-blockers reduce mortality by 35% and specifically reduce sudden cardiac death in patients with reduced LVEF (≤35-40%), but this benefit is unproven in those with preserved LVEF 7

Current Guideline Recommendations for Preserved LVEF Post-AMI

  • The 2024 ESC Guidelines explicitly acknowledge that there are no large RCTs supporting the prescription of beta-blockers after uncomplicated ACS in patients with LVEF >40% 1, 2, 3, 4
  • Beta-blockers are reasonable for symptom control if angina is present in patients with preserved LVEF (>40%) after uncomplicated MI 1, 2

Current Guideline Recommendations for Reduced LVEF Post-AMI

  • The American College of Cardiology/American Heart Association recommends evidence-based beta blockers in all patients with recent or remote MI and reduced EF to prevent symptomatic heart failure and reduce mortality 8, 9
  • Specific beta blockers proven in heart failure with reduced ejection fraction include bisoprolol, carvedilol, and extended-release metoprolol succinate 5

Ongoing Clinical Trials and Debate

  • Three large-scale European pragmatic RCTs are currently underway to definitively answer whether beta-blockers benefit post-ACS patients with preserved LVEF 1, 2, 3, 4
  • The optimal duration of beta-blocker therapy in patients with prior MI and preserved LVEF remains controversial, with some studies suggesting clinical benefit may be restricted to the first year after the index event 1, 2, 10, 3, 4

REFERENCES